Search the Community

Showing results for tags 'osteoarthritis of the knee'.

More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


  • Biotech Event Tracker


  • Biotech Stocks
    • General Biotech Investing Discussion
    • Daily Biotech Stock News
    • Biotech Forecast Course Discussion
  • Clinical, Regulatory and Company Catalysts
    • Event Tracker Discussion
    • Suggest Events to Add to the Event Tracker
  • Site Updates, Announcements, & Questions
    • Site Updates & Announcements


  • Files
  • Image Processing

Found 1 result

  1. "With positive clinical data from our pivotal registration trials that were presented at OARSI and the subsequent written indication from the FDA that the safety and efficacy data from the registration program for Zilretta are ‘acceptable to support filing of an NDA submission,' we moved forward in bolstering our commercial executive team and are now poised to submit an NDA with the FDA in the fourth quarter of this year. Our goal is to make Zilretta available to the many millions of knee osteoarthritis (OA) patients who lack good pain-relief options," said Michael Clayman, M.D., President and Chief Executive Officer of Flexion.